Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHVSBullishAnalyst Ratingnews

High materiality8/10

BoA Upgrade Highlights PHVS Dual-Oral HAE Opportunity and 2027 NDA Catalyst

Oct 23, 2026, 2:26 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A credible upgrade with a price target (to $44 implied by the note) and clear regulatory catalysts can attract buyers and lift multiple expansion, as seen when upgrades preceded NDA timelines in biotech.

AI summary

What happened, with direct paths to the underlying reporting

Bank of America Securities upgraded Pharvaris (PHVS) on reduced clinical risk, highlighting deucrictibant’s dual oral prophylaxis and on-demand potential for hereditary angioedema (HAE). The note projects 30–50% prophylaxis market share and up to $917 million in peak sales if a 2028 launch occurs, with an FDA NDA decision targeted for 2027. This sets up near-term upside on the upgrade and longer-term potential around regulatory milestones.

BoA upgrades PHVS citing attractive entry point and reduced clinical risk.
Deucrictibant offers dual oral prophylaxis and on-demand options for HAE.
NDA for on-demand deucrictibant under FDA review; decision set Apr 23, 2027.
Prophylaxis market share could reach 30–50%; peak sales ~$917 million (2028).
PHVS shares rose 2.74% to about $31.52 on the news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

BoA Upgrade Highlights PHVS Dual-Oral HAE Opportunity and 2027 NDA Catalyst

Pharvaris' oral HAE therapy hits primary endpoint in pivotal trial

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows